Preclinical Efficacy Data of Apogenix’ HERA – CD27L Published in Frontiers in Oncology

Home  >>  News  >>  Preclinical Efficacy Data of Apogenix’ HERA – CD27L Published in Frontiers in Oncology

Preclinical Efficacy Data of Apogenix’ HERA – CD27L Published in Frontiers in Oncology

On October 4, 2018, Posted by , In News, By , With Comments Off on Preclinical Efficacy Data of Apogenix’ HERA – CD27L Published in Frontiers in Oncology
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that new data published in the current volume of Frontiers in Oncology demonstrate the potent anti – tumor efficacy of Apogenix’ HERA – CD27L. In contrast to antibodies in development, HERA – CD27L is the first true CD27 receptor agonist with a well – defined mode of action that acts directly on immune cells, thereby enhancing their anti – tumor immunity.
Complete Press Release.

Related Post

Comments are closed.